• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Silent Heart Attack Market Trends

    ID: MRFR/Pharma/3563-HCR
    110 Pages
    Rahul Gotadki
    October 2025

    Silent Heart Attack Market Research Report Information By Diagnosis (CT, MRI, ECG, Blood Tests), Treatment (Medications, Coronary Angioplasty And Stenting, Coronary Artery Bypass Surgery), End-User (Hospital, Clinic, Diagnostic Center) -  Global Forecast till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Silent Heart Attack Market Infographic
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Market Trends

    Key Emerging Trends in the Silent Heart Attack Market

    High-sensitivity troponin testing is a vital pattern on the lookout for Silent Heart Attacks. These high-level blood tests offer more noteworthy sensitivity in detecting cardiac troponin, a protein delivered during a heart attack, empowering early ID of myocardial damage even in situations where side effects are missing or unobtrusive. The utilization of cutting-edge imaging modalities, including cardiac magnetic resonance imaging (MRI) and figured tomography (CT) angiography, is on the ascent. Market patterns show a developing dependence on these harmless methods to imagine cardiac structures, recognize myocardial infarctions, and survey heart health, especially in instances of Silent Heart Attacks. Wearable cardiac checking gadgets are turning out to be progressively common on the lookout. These gadgets, including smartwatches and versatile electrocardiogram (ECG) screens, empower consistent heart observing and ongoing detection of abnormalities, adding to the early distinguishing proof of Silent Heart Attacks. Artificial Intelligence (AI) is assuming a huge part in Silent Heart Assault detection. AI calculations break down complex information from demonstrative tests, imaging review, and wearable gadgets to distinguish designs characteristic of myocardial harm, helping healthcare experts in making ideal and precise analyses. The reception of telehealth administrations is filling in the Silent Heart Assault market. Telehealth stages empower far off cardiovascular checking, permitting patients to talk with cardiologists, go through symptomatic tests, and get continuous consideration without the requirement for successive in-person visits. Genetic and biomarker research is a striking pattern in the Silent Heart Assault market. Researchers are examining genetic inclinations and explicit biomarkers related with Silent Heart Attacks, aiming to foster designated mediations and recognize people at higher risk.

    Market Summary

    The Global Silent Heart Attack Market is projected to grow significantly from 5.16 USD Billion in 2024 to 15.0 USD Billion by 2035.

    Key Market Trends & Highlights

    Silent Heart Attack Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate of 10.21 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 15.0 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 5.16 USD Billion, reflecting the current demand for silent heart attack awareness and treatment.
    • Growing adoption of advanced diagnostic technologies due to increasing awareness of silent heart attacks is a major market driver.

    Market Size & Forecast

    2024 Market Size 5.16 (USD Billion)
    2035 Market Size 15.0 (USD Billion)
    CAGR (2025-2035) 10.21%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    Siemens (U.S.), Schiller AG, Midmark Corporation, Koninklijke Philips N.V. (Japan), Bionet (Korea), Welch Allyn (U.S.), Toshiba Medical Systems Corporation (Japan), AstraZeneca plc (U.K), Pfizer (U.S.), Sanofi (France), Merck & Co. (U.S.), Daiichi Sankyo Company Limited, Novartis AG (Germany), Bayer (Germany), Takeda Pharmaceutical Company Limited (Japan), Boehringer Ingelheim GmbH (Germany), Astellas Pharma Inc. (Japan), Johnson & Johnson (U.S.), United Therapeutics Corporation (U.S.), Actelion Pharmaceuticals Ltd. (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland)

    Market Trends

    The increasing prevalence of silent heart attacks, often undetected until significant damage occurs, underscores the urgent need for enhanced public awareness and preventive measures in cardiovascular health.

    Centers for Disease Control and Prevention (CDC)

    Silent Heart Attack Market Market Drivers

    Market Growth Projections

    The Global Silent Heart Attack Market Industry is poised for remarkable growth, with projections indicating a market value of 5.16 USD Billion in 2024 and an anticipated increase to 15.0 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate of 10.21% from 2025 to 2035, highlighting the increasing recognition of silent heart attacks as a critical health issue. Factors contributing to this growth include advancements in diagnostic technologies, rising awareness, and an aging population. The market's expansion reflects a broader commitment to improving cardiovascular health outcomes globally.

    Government Initiatives and Funding

    Government initiatives and funding aimed at cardiovascular health are pivotal in shaping the Global Silent Heart Attack Market Industry. Various health departments are allocating resources to research, prevention, and treatment programs focused on heart health. These initiatives often include public awareness campaigns, subsidized screenings, and funding for innovative research. Such support not only enhances the understanding of silent heart attacks but also encourages the development of new treatment modalities. As a result, the market is likely to witness substantial growth, with projections indicating a rise to 15.0 USD Billion by 2035, reflecting the impact of these governmental efforts.

    Advancements in Diagnostic Technologies

    Technological advancements in diagnostic tools are significantly influencing the Global Silent Heart Attack Market Industry. Innovations such as advanced imaging techniques and wearable health monitors enable early detection of heart conditions that may otherwise go unnoticed. These technologies facilitate timely interventions, potentially reducing mortality rates associated with silent heart attacks. The integration of artificial intelligence in diagnostic processes further enhances accuracy and efficiency. As the market evolves, the anticipated growth to 15.0 USD Billion by 2035 underscores the critical role of these advancements in improving patient outcomes and driving industry expansion.

    Aging Population and Increased Risk Factors

    The Global Silent Heart Attack Market Industry is notably impacted by the aging population, which is associated with a higher prevalence of cardiovascular diseases. As individuals age, the risk factors for silent heart attacks, such as hypertension and diabetes, become more pronounced. This demographic shift necessitates increased healthcare resources and interventions tailored to older adults. The market's projected compound annual growth rate of 10.21% from 2025 to 2035 reflects the urgent need for effective management strategies targeting this vulnerable population. Consequently, healthcare providers are focusing on preventive measures to mitigate risks and enhance quality of life.

    Increasing Awareness of Silent Heart Attacks

    The Global Silent Heart Attack Market Industry is experiencing growth driven by heightened awareness regarding silent heart attacks. Educational campaigns by health organizations emphasize the importance of recognizing risk factors and symptoms, even when they are not overtly present. This awareness is crucial, as silent heart attacks can lead to severe complications if left undetected. As individuals become more informed, they are more likely to seek preventive measures and screenings, contributing to market expansion. The projected market value of 5.16 USD Billion in 2024 reflects this growing consciousness, indicating a shift towards proactive health management.

    Rising Incidence of Lifestyle-Related Diseases

    The prevalence of lifestyle-related diseases, including obesity and diabetes, is a significant driver of the Global Silent Heart Attack Market Industry. Poor dietary habits, sedentary lifestyles, and increased stress levels contribute to the rising incidence of cardiovascular conditions. As these lifestyle factors become more common, the likelihood of silent heart attacks increases, prompting healthcare systems to adapt. Public health initiatives aimed at promoting healthier lifestyles are essential in addressing this issue. The market's growth trajectory, with an expected value of 5.16 USD Billion in 2024, indicates a response to the urgent need for effective interventions in lifestyle management.

    Market Segment Insights

    Regional Insights

    Key Companies in the Silent Heart Attack Market market include

    Industry Developments

    Future Outlook

    Silent Heart Attack Market Future Outlook

    The Silent Heart Attack Market is projected to grow at a 10.21% CAGR from 2024 to 2035, driven by increasing awareness and advancements in diagnostic technologies.

    New opportunities lie in:

    • Develop AI-driven diagnostic tools for early detection of silent heart attacks.
    • Expand telehealth services to monitor at-risk populations remotely.
    • Invest in educational campaigns to raise awareness about silent heart attack symptoms.

    By 2035, the Silent Heart Attack Market is expected to be robust, reflecting heightened awareness and improved healthcare solutions.

    Market Segmentation

    Intended Audience

    • Medical Device Manufacturers
    • Medical Device Suppliers
    • Medical Research Laboratories
    • Research and Development (R&D) Companies
    • Market Research and Consulting Service Providers
    • Potential Investors

    Key Players in the Silent Heart Attack Market

    • Siemens (U.S.)
    • Schiller AG
    • Midmark Corporation
    • Koninklijke Philips N.V. (Japan) 
    • Bionet (Korea)
    • Welch Allyn (U.S.)
    • Toshiba Medical Systems Corporation (Japan)
    • AstraZeneca plc (U.K)
    • Pfizer (U.S.)
    • Sanofi (France)
    • Merck & Co. (U.S.)
    • Daiichi Sankyo Company Limited
    • Novartis AG (Germany)
    • Bayer (Germany)
    • Takeda Pharmaceutical Company Limited (Japan)
    • Boehringer Ingelheim GmbH (Germany)
    • Astellas Pharma Inc. (Japan)
    • Johnson & Johnson (U.S.)
    • United Therapeutics Corporation (U.S.)
    • Actelion Pharmaceuticals Ltd. (Switzerland) 
    • F. Hoffmann-La Roche Ltd (Switzerland)
    • Medical Device Manufacturers
    • Medical Device Suppliers
    • Medical Research Laboratories
    • Research and Development (R&D) Companies
    • Market Research and Consulting Service Providers
    • Potential Investors

    Report Scope

    Attribute/Metric Details  
    Market Size USD 12.23 Billion by 2032  
    CAGR 7.14% (2024-2032)  
    Base Year   2023  
    Forecast Period   2024-2032  
    Historical Data Market Size 2023 4.53 (USD Billion)
    Forecast Units Market Size 2024 5.16 (USD Billion)
    Report Coverage Market Size 2032 12.23 (USD Billion)
    Segments Covered Compound Annual Growth Rate (CAGR) 7.14 % (2024 - 2032)
    Geographies Covered Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Key Vendors Base Year 2023
      Market Forecast Period 2024 - 2032
      Historical Data 2019 - 2023

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM

    FAQs

    What is the expected growth rate of the global silent heart attack market?

    silent heart attack market is expected to register 7.14% CAGR from 2024 to 2032.

    Which is the biggest driver of the global silent heart attack market?

    silent heart attack market is driven by high incidence of cardiovascular diseases.

    What factors can restrain the global silent heart attack market?

    High costs of diagnosis of heart conditions and lack of skilled professionals are factors which can hamper the global silent heart attack market.

    Which region can dominate the global silent heart attack market?

    The Americas can dominate the global silent heart attack market till 2032 due to rising cases of cardiovascular diseases.

    Name the notable players of the global silent heart attack market?

    Toshiba Medical Systems Corporation, Merck & Co., Takeda Pharmaceutical Company Limited, Bayer, Boehringer Ingelheim GmbH, Bionet, Midmark Corporation, Johnson & Johnson, United Therapeutics Corporation, Pfizer, Daiichi Sankyo Company Limited, Astellas Pharma Inc., F. Hoffmann-La Roche Ltd, Actelion Pharmaceuticals Ltd., Schiller AG, AstraZeneca plc, Sanofi, Welch Allyn, Koninklijke Philips N.V., Novartis AG, and Siemens are notable players of the global silent heart attack market.

    1. TABLE OF CONTENT
    2. Chapter 1. Report Prologue
    3. Chapter 2. Market Introduction
      1. Definition
      2. Scope of the Study
        1. Research Objective
        2. Assumptions
        3. Limitations
    4. Chapter 3. Research Methodology
      1. Introduction
      2. Primary Research
      3. Secondary research
      4. Market Size Estimation
    5. Chapter 4. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Challenges
      5. Macroeconomic Indicators
      6. Technology Trends & Assessment
    6. Chapter 5. Market Factor Analysis
      1. Porters Five Forces Analysis
        1. Bargaining Power of Suppliers
        2. Bargaining Power of Buyers
        3. Threat of New Entrants
        4. Threat of Substitutes
        5. Intensity of Rivalry
      2. Value Chain Analysis
      3. Investment Feasibility Analysis
      4. Pricing Analysis
    7. Chapter 6. Global Silent Heart Attack Market, by Diagnosis
      1. Introduction
      2. Cardiac computerized tomography
    8. Market Estimates & Forecast, 2020 – 2027
      1. magnetic resonance imaging
    9. Market Estimates & Forecast, 2020 – 2027
      1. electrocardiogram
      2. echocardiogram
      3. Blood Test
      4. Others
    10. Chapter 7. Global Silent Heart Attack Market, by Treatment
      1. Introduction
      2. Medications
      3. Coronary angioplasty and stenting
      4. Coronary artery bypass surgery
    11. Market Estimates & Forecast, 2020 – 2027
      1. Other
    12. Chapter 8 Global Silent Heart Attack Market, by End User
      1. Introduction
      2. Hospital
      3. Clinics
      4. Diagnostic Centers
      5. Others
    13. Chapter 9. Global Silent Heart Attack Market, by Region
      1. Introduction
      2. America
        1. North America
        2. South America
      3. Europe
        1. Western Europe
        2. Eastern Europe
      4. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia
        5. Republic of Korea
        6. Rest of Asia Pacific
      5. The Middle East & Africa
        1. United Arab Emirates
        2. Saudi Arabia
        3. Oman
        4. Kuwait
        5. Qatar
        6. Rest of the Middle East & Africa
    14. Chapter 10 Company Landscape
      1. Introduction
      2. Market Share Analysis
      3. Key Development & Strategies
        1. Key Developments
    15. Chapter 11 Company Profiles
      1. Siemens
        1. Company Overview
        2. Product Overview
        3. Financials
        4. SWOT Analysis
      2. Koninklijke Philips N.V.
        1. Company Overview
        2. Product Overview
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
      3. AstraZeneca plc
        1. Company Overview
        2. Product Overview
        3. Financial Overview
        4. Key Development
        5. SWOT Analysis
      4. Pfizer
        1. Company Overview
        2. Product/Business Segment Overview
        3. Financial Overview
        4. Key Development
        5. SWOT Analysis
      5. Sanofi
        1. Company Overview
        2. Product Overview
        3. Financial overview
        4. Key Developments
      6. Merck & Co.
        1. Company Overview
        2. Product Overview
        3. Financial Overview
        4. Key Developments
      7. F. Hoffmann-La Roche Ltd.
        1. Overview
        2. Product Overview
        3. Financials
        4. Key Developments
        5. SWOT Analysis
      8. Others
    16. Chapter 12 MRFR Conclusion
      1. Key Findings
        1. From CEO’s View Point
        2. Unmet Needs of the Market
      2. Key Companies to Watch
      3. Prediction of Pharmaceutical industry
    17. Chapter 13 Appendix
    18. List of Tables and Figures
      1. LIST OF TABLES
      2. Table 1 Silent Heart Attack Industry Synopsis, 2020 – 2027
      3. Table 2 Global Silent Heart Attack Market Estimates and Forecast, 2020 – 2027, (USD Million)
      4. Table 3 Global Silent Heart Attack Market by Region, 2020 – 2027, (USD Million)
      5. Table 4 Global Silent Heart Attack Market by Diagnosis, 2020 – 2027, (USD Million)
      6. Table 5 Global Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
      7. Table 6 Global Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
      8. Table 7 North America Silent Heart Attack Market by Diagnosis, 2020 – 2027, (USD Million)
      9. Table 8 North America Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
      10. Table 9 North America Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
      11. Table 10 US Market by Diagnosis, 2020 – 2027, (USD Million)
      12. Table 11 US Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
      13. Table 12 US Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
      14. Table 13 Canada Market by Diagnosis, 2020 – 2027, (USD Million)
      15. Table 14 Canada Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
      16. Table 15 Canada Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
      17. Table 16 South America Market by Diagnosis, 2020 – 2027, (USD Million)
      18. Table 17 South America Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
      19. Table 18 South America Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
      20. Table 19 Europe Market by Diagnosis, 2020 – 2027, (USD Million)
      21. Table 20 Europe Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
      22. Table 21 Europe Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
      23. Table 22 Western Europe Market by Diagnosis, 2020 – 2027, (USD Million)
      24. Table 23 Western Europe Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
      25. Table 24 Western Europe Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
      26. Table 25 Eastern Europe Market by Diagnosis, 2020 – 2027, (USD Million)
      27. Table 26 Eastern Europe Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
      28. Table 27 Eastern Europe Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
      29. Table 28 Asia Pacific Market by Diagnosis, 2020 – 2027, (USD Million)
      30. Table 29 Asia Pacific Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
      31. Table 30 Asia Pacific Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
      32. Table 31 Middle East & Africa Market by Diagnosis, 2020 – 2027, (USD Million)
      33. Table 32 Middle East & Africa Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
      34. Table 33 Middle East & Africa Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million) LIST OF FIGURES
      35. Figure 1 Research Process
      36. Figure 2 Segmentation for Global Silent Heart Attack Market
      37. Figure 3 Segmentation Market Dynamics for Global Silent Heart Attack Market
      38. Figure 4 Global Silent Heart Attack market Share, by Type 2020
      39. Figure 5 Global Silent Heart Attack market Share, by Treatment 2020
      40. Figure 6 Global Silent Heart Attack Market Share, by End Users, 2020
      41. Figure 7 Global Silent Heart Attack Market Share, by Region, 2020
      42. Figure 8 North America Silent Heart Attack Market Share, by Country, 2020
      43. Figure 9 Europe Silent Heart Attack Market Share, by Country, 2020
      44. Figure 10 Asia Pacific Silent Heart Attack Market Share, by Country, 2020
      45. Figure 11 Middle East & Africa Silent Heart Attack Market Share, by Country, 2020
      46. Figure 12 Global Silent Heart Attack Market: Company Share Analysis, 2020 (%)
      47. Figure 13 Siemens: Key Financials
      48. Figure 14 Siemens: Segmental Revenue
      49. Figure 15 Siemens: Geographical Revenue
      50. Figure 16 Koninklijke Philips N.V.: Key Financials
      51. Figure 17 Koninklijke Philips N.V.: Segmental Revenue
      52. Figure 18 Koninklijke Philips N.V.: Geographical Revenue
      53. Figure 19 AstraZeneca plc: Key Financials
      54. Figure 20 AstraZeneca plc: Segmental Revenue
      55. Figure 21 AstraZeneca plc: Geographical Revenue
      56. Figure 22 Pfizer: Key Financials
      57. Figure 23 Pfizer: Segmental Revenue
      58. Figure 24 Pfizer: Geographical Revenue
      59. Figure 25 Sanofi.: Key Financials
      60. Figure 26 Sanofi.: Segmental Revenue
      61. Figure 27 Sanofi.: Geographical Revenue
      62. Figure 28 F. Hoffmann-La Roche Ltd.: Key Financials
      63. Figure 29 F. Hoffmann-La Roche Ltd.: Segmental Revenue
      64. Figure 30 F. Hoffmann-La Roche Ltd.: Geographical Revenue
      65. Figure 31 AstraZeneca Plc: Key Financials
      66. Figure 32 AstraZeneca Plc: Segmental Revenue
      67. Figure 33 AstraZeneca Plc.: Geographical Revenue

    Silent Heart Attack Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials